Compare Ascendis Pharma A/S (ASND) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Symbotic Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Symbotic Inc trades at $43.4 (market cap $5.55B). The key difference: Ascendis Pharma A/S is far larger — about 3.2× Symbotic Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| ASND | SYM | |
|---|---|---|
Market Cap | $17.74B | $5.55B |
Sector | Health | Technology |
52-Week High | $277.18 | $87.30 |
52-Week Low | $163.32 | $38.57 |
Enterprise Value | $18.11B | $3.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SYM trades at $43.64, up 1.14% with neutral technical signals. The company reported $2.25B revenue in 2025 but a net loss of $16.94M, though margins are improving. Recent acquisition of ARMS Innovations expands warehouse automation capabilities. Analyst consensus is bullish with a $57.50 price target, representing 32% upside potential from current levels.
Outlook remains positive due to strong revenue growth and expanding automation market, but profitability challenges and competitive pressures present risks. The stock offers growth potential but requires monitoring of earnings trajectory and market position in the evolving robotics sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
